WO2009117987A3 - Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g - Google Patents

Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g Download PDF

Info

Publication number
WO2009117987A3
WO2009117987A3 PCT/DE2009/000385 DE2009000385W WO2009117987A3 WO 2009117987 A3 WO2009117987 A3 WO 2009117987A3 DE 2009000385 W DE2009000385 W DE 2009000385W WO 2009117987 A3 WO2009117987 A3 WO 2009117987A3
Authority
WO
WIPO (PCT)
Prior art keywords
boswellia
acid derivatives
cathepsin
synthetic
synthase
Prior art date
Application number
PCT/DE2009/000385
Other languages
English (en)
French (fr)
Other versions
WO2009117987A2 (de
Inventor
Oliver Werz
Joachim-Friedrich Kapp
Roland Martin
Original Assignee
Universität Tübingen
Medeon Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102008015607A external-priority patent/DE102008015607A1/de
Priority claimed from DE102008017496A external-priority patent/DE102008017496A1/de
Application filed by Universität Tübingen, Medeon Pharmaceuticals Gmbh filed Critical Universität Tübingen
Publication of WO2009117987A2 publication Critical patent/WO2009117987A2/de
Publication of WO2009117987A3 publication Critical patent/WO2009117987A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die vorliegende Erfindung betrifft neue Boswelliasäurederivate. Die vorliegende Erfindung betrifft ferner die Verwendung von Zubereitungen mit Boswelliasäuren bzw. synthetischer Derivate insbesondere Boswelliasäure-Derivate, die an der C3-OH-Funktion verestert oder verethert sind, zur Hemmung der induzierbaren mikrosomalen Prostaglandin E2 Synthase-1 und/oder zur Hemmung des Cathepsin G. Ferner betrifft die Erfindung Verwendung von Boswelliasäuren bzw. synthetischer Derivate zur Herstellung eines Arzneimittels zur Behandlung von PGE2- und/oder Cathepsin G-vermittelter krankhafter Zustände.
PCT/DE2009/000385 2008-03-26 2009-03-25 Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g WO2009117987A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102008015607A DE102008015607A1 (de) 2008-03-26 2008-03-26 Verwendung von Boswelliasäuren und synthetischen Boswelliasäurederivaten zur Hemmung der mikrosomalen Prostaglandin E2 Synthase und des Cathepsin G
DE102008015607.8 2008-03-26
DE102008017496.3 2008-04-04
DE102008017496A DE102008017496A1 (de) 2008-04-04 2008-04-04 Verwendung von Boswelliasäure und Boswelliasäurederivaten zur Herstellung von Arzneimitteln zur Therapie von Multipler Sklerose

Publications (2)

Publication Number Publication Date
WO2009117987A2 WO2009117987A2 (de) 2009-10-01
WO2009117987A3 true WO2009117987A3 (de) 2009-12-03

Family

ID=40942410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2009/000385 WO2009117987A2 (de) 2008-03-26 2009-03-25 Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g

Country Status (1)

Country Link
WO (1) WO2009117987A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
TW202124450A (zh) 2019-10-18 2021-07-01 美商四十七股份有限公司 用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
KR20230006891A (ko) 2020-05-01 2023-01-11 길리애드 사이언시즈, 인코포레이티드 Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
CN112225775A (zh) * 2020-10-28 2021-01-15 籍建亚 一种抗菌消炎熊果酸衍生物及其制备方法
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
EP4359389A1 (de) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercolkinase modulierende verbindungen
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04288095A (ja) * 1991-01-22 1992-10-13 Tsumura & Co 補体活性抑制剤
EP0755940A1 (de) * 1995-04-13 1997-01-29 Council of Scientific and Industrial Research Boswellsäure Zusammensetzungen und die Herstellung davon
WO2003099302A1 (en) * 2002-05-24 2003-12-04 Turispharma S.R.L. A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere
CN1615888A (zh) * 2004-08-31 2005-05-18 凌沛学 一种药物组合物及其用途
WO2005123649A1 (en) * 2004-06-18 2005-12-29 Ganga Raju Gokaraju NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID
WO2008058514A1 (de) * 2006-11-14 2008-05-22 Eberhard Karls Universität Tübingen Zubereitungen enthaltend boswelliasäuren zur hemmung der prostaglandin e2 synthese

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04288095A (ja) * 1991-01-22 1992-10-13 Tsumura & Co 補体活性抑制剤
EP0755940A1 (de) * 1995-04-13 1997-01-29 Council of Scientific and Industrial Research Boswellsäure Zusammensetzungen und die Herstellung davon
WO2003099302A1 (en) * 2002-05-24 2003-12-04 Turispharma S.R.L. A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere
WO2005123649A1 (en) * 2004-06-18 2005-12-29 Ganga Raju Gokaraju NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID
CN1615888A (zh) * 2004-08-31 2005-05-18 凌沛学 一种药物组合物及其用途
WO2008058514A1 (de) * 2006-11-14 2008-05-22 Eberhard Karls Universität Tübingen Zubereitungen enthaltend boswelliasäuren zur hemmung der prostaglandin e2 synthese

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HAYASHI, KOJI ET AL: "Complement inhibitors containing .beta.-boswellic acid (derivatives)", XP002541974, retrieved from STN Database accession no. 1993:109686 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LING, PEIXUE ET AL: "Manufacture of medicine composition for treating rheumatic arthritis and rheumatoid arthritis", XP002541975, retrieved from STN Database accession no. 2005:1257930 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANEJA, SUBHASH CHANDRA ET AL: "A process for the preparation of O-acylates of .beta.-boswellic acids", XP002541976, retrieved from STN Database accession no. 2003:971411 *
MAHAJAN, BABITA ET AL: "Two triterpenoids from Boswellia serrata gum resin", PHYTOCHEMISTRY , 39(2), 453-5 CODEN: PYTCAS; ISSN: 0031-9422, 1995, XP002541973 *

Also Published As

Publication number Publication date
WO2009117987A2 (de) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009117987A3 (de) Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g
WO2007127377A3 (en) Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2008036653A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2010078512A3 (en) Production of substituted phenylene aromatic diesters
WO2011139702A3 (en) Modified nucleosides and oligomeric compounds prepared therefrom
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
WO2008070268A3 (en) Pharmaceutical compositions
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011141909A3 (en) Lipoic acid and nitroxide derivatives and uses thereof
WO2011039735A3 (en) Compounds with ddx3 inhibitory activity and uses thereof
WO2009100183A3 (en) Variant buttiauxela sp. phytases having altered properties
WO2007095383A3 (en) Prodrugs
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2009124962A3 (en) Sulfonamides
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2007023342A3 (en) Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof
WO2009040113A3 (en) C5a BINDING NUCLEIC ACIDS
WO2009149921A8 (en) Inhibition of hrp-3 using modified oligonucleotides
WO2009040314A3 (de) Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2
WO2009118589A3 (en) Orally disintegrating compositions of rhein or diacerein
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2011088160A3 (en) Novel cyp17 inhibitors
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723945

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09723945

Country of ref document: EP

Kind code of ref document: A2